News

The Harrington Discovery Institute and The American Society for Clinical Investigation honor Dr. Orkin for his contributions to red blood cell biology.

The report’s authors include investigators from Dana-Farber, Brigham and Women’s, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, the Broad Institute of MIT and Harvard, and Pitié-Salpêtrière hospitals in Paris, France, among others.

Daniel Bauer, MD, PhD, is a physician-scientist whose research focuses on functional genomics to dissect determinants of blood cell development and disease and develop innovative therapies.

Strategies to bar the coronavirus (COVID-19) from entering cells — thereby preventing infection and averting transmission of the virus — are among the most promising treatment approaches to COVID-19.

Dana-Farber/Boston Children’s physicians have implemented crucial testing protocols during this unusual time, with a focus that children with cancer need life-saving treatments even in the setting of a viral pandemic.

Past recipients with ties to Dana-Farber/Boston Children’s include Joanne Wolfe, MD, MPH (2016); Scott A. Armstrong, MD, PhD (2014); David Williams, MD (2006); and Stuart Orkin, MD (2003).

The patient-partnered initiative will enable anyone in the USA and Canada affected by osteosarcoma to participate.

The clinical trial will investigate the effectiveness of a combination of two oral drugs targeting the DNA damage response pathway.

Dr. Baird specializes in the care of children with neurological disorders of the brain and spine, with specific expertise in brain and spinal cord tumors, cerebrovascular malformations, and skull base neurosurgery.

Daphne Haas-Kogan, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, will receive a research grant totaling $600,000 over three years for “Dependence of DIPGs on DNA polymerase q for DNA repair defines a new therapeutic target.”